Shameze Rampertab - 22 Aug 2024 Form 4 Insider Report for ASENSUS SURGICAL, INC.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
22 Aug 2024, 09:08:57 UTC
Prior SEC filing
23 Apr 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua Weingard as attorney-in-fact for Shameze Rampertab

Key filing fact

Shameze Rampertab filed Form 4 for ASENSUS SURGICAL, INC. on 22 Aug 2024.

Key facts

  • This page summarizes Shameze Rampertab's Form 4 filing for ASENSUS SURGICAL, INC..
  • 6 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 22 Aug 2024, 09:08.

Change

  • Previous filing in this sequence was filed on 23 Apr 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASXC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-595,372
Change %
-100%
Price
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASXC transaction Derivative

Stock Options

Disposed to Issuer

Transaction value
$0
Shares
-396,800
Change %
-100%
Price
$0.000000
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
396,800
Exercise price
$0.2600
Footnotes
F3
ASXC transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
$0
Shares
-116,666
Change %
-100%
Price
$0.000000
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
116,666
Exercise price
$0.000000
Footnotes
F4, F6
ASXC transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
$0
Shares
-62,417
Change %
-100%
Price
$0.000000
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
62,417
Exercise price
$0.000000
Footnotes
F4, F6
ASXC transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
$0
Shares
-330,300
Change %
-100%
Price
$0.000000
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
330,300
Exercise price
$0.000000
Footnotes
F5, F6
ASXC transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
$0
Shares
-660,600
Change %
-100%
Price
$0.000000
Shares after
0
Date
22 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
660,600
Exercise price
$0.000000
Footnotes
F4, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Shameze Rampertab is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.

Footnote F2

The reported securities include 179,084 shares of common stock issued upon the acceleration and vesting of performance-based restricted stock units.

Footnote F3

Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.09 per underlying share of common stock only upon satisfaction of all vesting conditions.

Footnote F4

Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock.

Footnote F5

Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock.

Footnote F6

Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .